RxDoctor Payments Data

Kelechukwu Okoro, MD

Interventional Cardiology · Thomasville, GANPI 1669869152

Payments from drug & device makers

$30,372in general payments, 2019–2025

Across 423 payments — averaging $71.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Medtronic$5K
  • Boston Scientific$3K
  • Penumbra, Inc.$2K
  • Abiomed$2K
  • Edwards Lifesciences$2K
  • plus $9K from 25 others

What the payments were for

  • Grants$3491%
  • Travel & lodging$16,05953%
  • Food & beverage$13,31544%
  • Education$6492%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,372 in reported general payments places this provider in the 70th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$77,339
Medicare patients
438
Services billed
826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis36$932,793
EntrestoSacubitril/Valsartan297$299,732
EliquisApixaban282$199,075
FarxigaDapagliflozin Propanediol177$144,863
JardianceEmpagliflozin124$122,903
BrilintaTicagrelor54$37,190
XareltoRivaroxaban30$32,595
Repatha SureclickEvolocumab12$12,923
Ranolazine ErRanolazine135$8,653
Metoprolol Succinate407$3,985
Rosuvastatin Calcium209$2,774
Isosorbide Mononitrate ErIsosorbide Mononitrate215$1,943
Atorvastatin Calcium236$1,568
Isosorbide Dinitrate52$1,250
Carvedilol190$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$299$1,131,868318 claims
NovartisEntresto$39$299,732297 claims
AstraZenecaFarxiga, Brilinta$918$182,053231 claims
Boehringer IngelheimJardiance$169$122,903124 claims
Johnson & JohnsonXarelto$122$32,59530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →